Sign in to view Robert’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
London, England, United Kingdom
Sign in to view Robert’s full profile
Robert can introduce you to 10+ people at Multiomic Health
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
2K followers
500+ connections
Sign in to view Robert’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Robert
Robert can introduce you to 10+ people at Multiomic Health
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Robert
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Robert’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
About
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Articles by Robert
-
Hidden Risks for Pharma Companies Collaborating with Academia and Small Biotechs
Hidden Risks for Pharma Companies Collaborating with Academia and Small Biotechs
I was asked by the news and analysis service The Pharma Letter to author a bylined article on the collaboration risks…
14
1 Comment -
What are the levers for productivity improvement in a bioscience R&D organization?Mar 3, 2016
What are the levers for productivity improvement in a bioscience R&D organization?
Since the start of 2016, three interesting independent studies have been published on pharma R&D productivity. In…
23
5 Comments
Activity
2K followers
-
Robert Thong reposted thisRobert Thong reposted thisThe 8th CKD Drug Development Summit kicked off in Boston yesterday, setting the stage for insightful discussions on the future of kidney disease innovation. On the agenda today, our CEO, Robert Thong, is chairing the Discovery, Preclinical & Translational track, and tomorrow he will be joining a panel alongside Navdeep Tangri, Savithri Kota and Sona Barth, exploring key themes including the role of AI in renal drug R&D. If you're attending, be sure to drop by and join the discussion. #ckd #drugdevelopment #conference
-
Robert Thong shared thisBeing a startup CEO in healthcare and life sciences is tough. Nevertheless, Camilla Easter of Oxford Medical Products is one of the best and most balanced, I am honoured to know her and be on her board.Robert Thong shared thisTo mark International Women’s Day, hear from our CEO Dr. Camilla Easter on the ‘A Call to Lead’ podcast about what it’s really like to lead a startup. Building a company in healthcare is challenging, it requires resilience, adaptability, and the confidence to navigate uncertainty. But it’s also an incredibly rewarding path, with the opportunity to turn bold ideas into technologies that can improve patients’ lives. 🎧 In this episode, Camilla shares the realities of startup leadership, the lessons learned along the way, and why more women should consider entrepreneurship in science and healthcare. Listen to the full episode here: https://lnkd.in/ehJQKPdE Thank you to David Kirk for the conversation and for the opportunity to share more about what we are building at Oxford Medical Products. #InternationalWomensDay #WomenInHealthTech #WomenInSTEM #FemaleLeadership #StartupLife #OxfordMedicalProducts
-
Robert Thong shared thisVery humbled to be leading this incredible teamRobert Thong shared thisToday we’re celebrating a big milestone - MultiOmic Health turns 5! 🎂 It all began with one question: what biological mechanisms keep cardio-renal-metabolic (CRM) patients’ disease progressing despite current treatment paradigms? Inspired by the impact precision medicine has had in oncology, we set out to bring that same transformation to CRM. In our pursuit of this mission, the last 5 years have brought about some exciting milestones: • 5+ research collaborations initiated, powering scientific insights with data from over 300,000 CRM patients • Proof-of-principle demonstrated in chronic kidney disease, developing a method for patient stratification and endotype prediction (patent pending), and prioritising 6 novel drug targets • First biopharma partnership signed with Alloy Therapeutics, Inc. to develop 2 renal programs • Signed collaboration and option agreement for a preclinical asset as the basis for a third program Along the way, we’ve also gained many invaluable insights, including the commitment needed to generate truly high-quality patient datasets, how to foster strong, mutually rewarding partnerships, and strategies for adapting within the ever-changing biotech landscape. Looking back, we’re incredibly proud of the team we’ve grown, the science we’ve advanced, and the partnerships we’ve built along the way - each one an important part of our story. Special thanks to everyone who’s supported the MOH journey so far, including Richard Nkulikiyinka, Phil Kalra, Angeli Möller, Cristina Balagué, Alasdair Thong and all our investors, collaborators, and team members. Here’s to the next 5 years! #Startup #Biotech #Milestone #Innovation
-
Robert Thong shared thisLook forward to catching up with you allRobert Thong shared thisLooking forward to BioIndustry Association (BIA)'s annual TechBio UK event tomorrow! It's a great opportunity to hear from experts and gain insights into the latest developments shaping the field. Robert Thong and Henrietta Bull will be there representing MultiOmic - feel free to reach out or say hi if you’re attending. Always great to connect with others driving innovation in the TechBio community. #TechBioUK #BIA #Innovation
-
Robert Thong reposted thisRobert Thong reposted thisThe COVID-19 pandemic taught us many things. There were the lighter lessons (how to bake banana bread, how to master a Zoom quiz). And the darker truths: medical supply chains are fragile and sovereign health has long been neglected. As nations scrambled to get on top of the virus, those without their own drug-making capacity struggled to access lifesaving treatments quickly enough. Countries like the UK still face significant shortages in medicines for common conditions like diabetes, ADHD and epilepsy. In an increasingly volatile world, the UK’s health sovereignty is as vital to our national security as energy, defence, or agriculture. And as we race towards the era of 100-year life expectancy, the need for radical modernisation in our health systems could not be greater. 🧬That’s where ‘bio-infrastructure’ comes in A term coined by Alasdair Thong and me at Ada Ventures, it describes the emerging market of startups which sit at the intersection of health, deep-tech, digital infrastructure and AI. These aren’t your traditional drug developers or medical software companies. Instead, think AI that optimises clinical trial design, cloud platforms that enable scientists to experiment without physically being in the lab, or AI agents that can produce regulatory filings, allowing humans to focus on the science. This is the infrastructure we’ll need to build resilient, future-ready health systems. Check out my full piece below on why governments must invest in sovereign bio-infrastructure and how they can support the home-grown startups leading the way 🇬🇧
-
Robert Thong reposted thisRobert Thong reposted thisWe’re excited to share that we will be attending the European Association for the Study of Diabetes e.V. (EASD) 2025 Annual Meeting in Vienna this week. As part of one of the world’s leading diabetes research gatherings, we look forward to connecting with researchers, clinicians, and industry partners to explore new insights and collaborations at the cutting edge of diabetes and metabolic disease science. If you’re attending, we’d love to meet — please reach out to Rebecca Fairclough or Henrietta Bull who will be representing us there. #EASD2025 #DiabetesResearch #DKD
-
Robert Thong shared thisWe’re excited at the opportunity to work with the BIO4 Campus Belgrade and Serbia’s top tier life science research institutes and healthcare providers. #cardiorenalmetabolic #techbio #aiRobert Thong shared thisWe’re thrilled to announce that MultiOmic Health has signed a Memorandum of Understanding with Serbia’s flagship BIO4 Campus Belgrade to advance precision medicine and fuel the country’s burgeoning bioeconomy ecosystem. This collaboration will focus on applying AI-enabled, multi-omics approaches, spanning genetics, epigenetics, transcriptomics, proteomics, and metabolomics, to better understand and stratify patient endotypes in cardio-renal-metabolic diseases. Together, we’re set to create AI-powered tools, identify novel drug targets, and ultimately deliver more personalised, effective treatment options. Partnering with BIO4 and its network of leading research and clinical institutions reinforces our commitment to harnessing AI, data science, and translational biology for global patient impact. Learn more about this exciting collaboration here: https://lnkd.in/grHsA-qK
-
Robert Thong reposted thisRobert Thong reposted thisWe’re excited to share a major update: Multiomic Health has identified novel patient endotypes and biomarkers for diabetic kidney disease (DKD)! These discoveries allow for precise patient segmentation and could significantly improve both clinical trial success rates and personalised care for DKD patients. Our CEO Robert Thong will present more on these findings at the LSX - partnering for Life Science eXecutives Investival Conference in London on November 18. #PrecisionMedicine #DiabeticKidneyDisease #AIMultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease | SciadMultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease | Sciad
-
Robert Thong reposted thisRobert Thong reposted this*Bio-infrastructure* - a new term and market landscape we are launching today at Ada Ventures with Alasdair Thong our Venture Partner for Health to capture the opportunity in investing in the enabling stack - the picks and shovels of the 100-year life. By the middle of the century, there will be 2 billion people over the age of 60. We need to build a health care system that is fitting for this coming reality - one that is proactive, preventative, affordable and fair. While much of the investment discourse around longevity still centres on biohacking and individual optimisation, our focus is on the companies building practical, scalable solutions for the here and now - and for *everyone*. We are mapping the data, tools, and platforms heralded by the era of the 100-year life. We refer to this investment category as “Bio-Infrastructure”. I believe that this is the new backbone of health 🧬: Lab Automation – Empowering research with seamless, shared tools Autom Patient Data Platforms – Secure, inclusive access to diverse health data Bio‑Manufacturing – Scaling advanced therapies (think gene, mRNA) Reg‑tech Infrastructure – Ensuring devices and wearables are safe, secure, and equitable Talent + Workforce – Building the skills needed to sustain next‑gen healthcare This isn't just about software. It's hardware, servers, clinics—and the AI needed to connect them all. We'd love your views on this - what pillars are missing? Are the names right? Are there companies missing? Where do we need to build capacity? Link to the full map in the comments. Thanks to all the Ada Ventures founders building these remarkable companies - and if you are building in this space and we haven't met, please get in touch.. Julia Fan Li, PhD Amber Michelle H. Robert Thong Jason Mellad Rachael Crook Hana Janebdar Emily Chan CC Diarra Smith Matt Penneycard Matt Clifford Kate Bingham Milad Alucozai Anne Boden Azeem Azhar James Field Prof. Manoj Ramachandran Thank you to our friends at Mills & Reeve for the support in putting this together.
-
Robert Thong liked thisRobert Thong liked thisAs I begin my role as Chief Medical Officer, Innovative Medicine at Johnson & Johnson, I have been engaged in listening, learning, and reflecting. I was initially drawn to this position due to Johnson & Johnson’s innovative portfolio, which reflects the Company’s ambition to tackle significant healthcare challenges and the belief that these challenges can be addressed. A few early impressions have stood out. First, the Office of the Chief Medical Officer (OCMO) offers a unique perspective where science, safety, and impact converge. OCMO plays a vital role in providing bioethical guidance, fostering proactive safety science innovation, and making decisions informed by real-world evidence throughout the life cycle of a medicine. From early development to post-market safety surveillance, we emphasize rigorous evidence and patient-centered solutions, and I look forward to contributing to these efforts. Second, the people. I have had the opportunity to meet many team members and have observed a shared desire to advance science and improve outcomes for patients. Throughout my interactions, I have witnessed a genuine commitment to placing patients at the heart of every decision. It is evident that everyone here understands the direct impact our choices have on individuals during pivotal moments in their lives. Third, the focus on Our Credo. I am continually reminded of the immense responsibility we bear in creating innovative solutions for patients, recognizing that every advancement can profoundly affect lives. Looking ahead, I am eager to build on this foundation, advancing science with purpose and always keeping patients at the center of our efforts. Thank you to my colleagues for the warm welcome. I am excited about the work we will accomplish in support of the patients we serve.
-
Robert Thong liked thisThanks Brad Loncar for a great chat at Alloy R&D day. I appreciate all your great coverage of the industry trends and real time news!Robert Thong liked this𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Alloy Therapeutics, Inc. announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day Full video: https://lnkd.in/eyvtxwJ9 He discusses the Biogen deal, and how it is a sign of increased activity Alloy sees in their genetic medicines business. Plus, monoclonals vs multispecifics, and the state of discovery work today. BiotechTV is brought to you by: Mispro | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Genezen | Orchestra | Evaluate Ltd
-
Robert Thong liked thisI’m excited to announce that Centessa Pharmaceuticals has entered into a definitive agreement to be acquired by Eli Lilly and Company. We expect the transaction to close in the third quarter of 2026, subject to customary closing conditions, including regulatory approvals. Since founding our program in 2019, we have been driven to deliver transformative therapies for patients living with conditions that have long been underserved. This mission has shaped our collective efforts - from building our OX2R agonist portfolio to advancing cleminorexton and our broader pipeline. I am extremely grateful to our patients and study participants who continue to support our clinical studies. You are all a constant source of inspiration. To the Centessa team, your dedication and passion turned a bold scientific vision into a portfolio that defines the field. And to our shareholders and partners, thank you for believing in our mission. Joining Lilly will open a new chapter for Centessa. Their global and complementary research, clinical, regulatory and commercial expertise will help accelerate our orexin programs across neuroscience, bringing us closer to the patients who need new therapies most. I’m excited for what we can achieve together! Please refer to today’s full announcement for key information and cautionary statements: https://lnkd.in/eyY3dhW6Robert Thong liked thisToday, we announced that Centessa Pharmaceuticals has entered into a definitive agreement to be acquired by Eli Lilly and Company. We expect the transaction to close in the third quarter of 2026, subject to customary closing conditions, including regulatory approvals. What started as a scientific vision has grown into a class-leading OX2R agonist portfolio anchored by cleminorexton (formerly ORX750) — with best-in-class potential in NT1, NT2, and IH, and first-in-class potential in NT2 and IH. The progress across our orexin portfolio and discovery pipeline speaks to the extraordinary work of our team. To everyone who has been part of this journey — thank you. We also want to extend our deepest gratitude to the investigators, patients, and community advocates whose dedication makes the development of our candidates possible. Please refer to today’s full announcement for key information and cautionary statements: https://lnkd.in/egDUuKbG
-
Robert Thong liked thisRobert Thong liked thisThank you to Shawn Badal, PhD for running the discussion session exploring the roadmap for designing next generation kidney organoids that better recapitulate kidney function and #CKDpathology. Major topics discussed include: 🚨 How can we generate functional data to assess the function of different cell types in kidney organoids 🚨 How can we recapitulate filtration in kidney organoids and proximal tubules that are immature and don’t do transport 🚨 How can we engineer cells so that function better resembles kidney function It's not too late if you'd like to join for the final day tomorrow... 🔗 Event Guide: https://ter.li/obxwz1 🔗 Register: https://ter.li/ak47x8 #CKDSummit #CKD3 #NephrologyResearch #CKDDrugDevelopment #KidneyResearch #KidneyDrugDevelopment #ChronicKidneyDisease #CKDmodels #kidneymodel #kidneyorganoid
-
Robert Thong liked thisGreat discussion to kick off the 2026 CKD SummitRobert Thong liked thisIt was a pleasure to kick off day 1 of the #CKDSummit with a panel on advancing drug development in Cardiovascular-Kidney-Metabolic Syndrome, moderated by Pablo Cabral, Executive Director of External Innovation at Eli Lilly and Company Thank you to Aliza Thompson bringing the FDA perspective, Joseph Kupferman providing the sponsor lens from AstraZeneca and Matthias Kretzler bringing rich physician expertise from University of Michigan, this has been an impactful start to the day. Key takeaways include... 👉 Exploring our evolving understanding of pathophysiology linking cardiovascular, kidney and metabolic disorders 👉 Identifying when and how overlapping CKM phenotypes can be leveraged to design more efficient clinical trials 👉 Discuss next steps in integrated drug development ad regulatory frameworks for CKM components with shared mechanistic drivers It's not too late if you'd like to join for the final day tomorrow... 🔗 Event Guide: https://ter.li/obxwz1 🔗 Register: https://ter.li/ak47x8 #CKDSummit #CKD3 #NephrologyResearch #CKDDrugDevelopment #KidneyResearch #KidneyDrugDevelopment #ChronicKidneyDisease #CVRM #Cardiorenal #CKMResearch
-
Robert Thong liked thisRobert Thong liked thisIt began with a brilliant biological insight from Jaideep Dudani and a trip to Chengdu to meet the gracious team at Keymed Biosciences - and has resulted in a $2.2Bn exit to Gilead Sciences. What a wild ride, with enormous thanks due to the early trust from Bo Chen, Chris Sheldon, PhD and my partner Fred Cohen. With high conviction from our partners at TPG, Norwest and New Enterprise Associates (NEA) (Shinichiro Fuse, Brian Matesic, MD, Matthew McAviney, M.D.) Amazing execution from Neely Mozaffarian, M.D., Ph.D., Christina Carlson and Tyler Chavez and the whole Ouro Medicines team. Finally, to Gilead who recognised the long-term opportunity and will strive to deliver this therapy to patients with chronic autoimmune disease. ... and a special shout out to my Monograph Capital colleague Charlie Zhou who has seen this through from the beginning. (No pandas were harmed in the making of Ouro)
-
Robert Thong liked thisGlad to be part of a great panel Navdeep Tangri Sona Barth Robert Thong. Couldn't agree more with Navdeep- we stand at a pivotal moment to unlock AI’s full potential in transforming kidney disease research, drug discovery, and patient care.Robert Thong liked thisA huge thank you to Savithri Kota, Director of Precision Nephrology at Bayer for moderating a much anticipated panel evaluating How Can we Best Apply AI for Streamlined Drug Discovery in CKD? Expert panelists included: ⚡ Navdeep Tangri, Professor of Medicine at the University of Manitoba ⚡ Robert Thong, Co-Founder & CEO at Multiomic Health ⚡ Sona Barth, Principal Scientist of Discovery Nephrology at Roche Key Discussion topics included: ❇️ How AI and #machinelearning are being applied to target identification, protein engineering, and biomarker discovery in CKD, with a focus on DKD ❇️ Case studies and strategies from different labs and companies to understand the practical implementation and evolving performance of AI tools ❇️ Integration of AI across preclinical and clinical stages to accelerate precision nephrology research and development ❇️ Collaborative approaches and future frameworks, including shared strategies or white papers, to advance AI use in kidney disease drug discovery and beyond If you'd like to stay tuned for the 2027 edition of the 9th CKD Summit, register your interest here... 🔗https://ter.li/yf88yw #CKDSummit #CKD3 #CKDresearch #CKDDrugDevelopment #NephrologyResearch #KidneyResearch #KidneyDrugDevelopment #ChronicKidneyDisease #CKDDrugDiscovery
-
Robert Thong liked thisRobert Thong liked thisA huge thank you to Savithri Kota, Director of Precision Nephrology at Bayer for moderating a much anticipated panel evaluating How Can we Best Apply AI for Streamlined Drug Discovery in CKD? Expert panelists included: ⚡ Navdeep Tangri, Professor of Medicine at the University of Manitoba ⚡ Robert Thong, Co-Founder & CEO at Multiomic Health ⚡ Sona Barth, Principal Scientist of Discovery Nephrology at Roche Key Discussion topics included: ❇️ How AI and #machinelearning are being applied to target identification, protein engineering, and biomarker discovery in CKD, with a focus on DKD ❇️ Case studies and strategies from different labs and companies to understand the practical implementation and evolving performance of AI tools ❇️ Integration of AI across preclinical and clinical stages to accelerate precision nephrology research and development ❇️ Collaborative approaches and future frameworks, including shared strategies or white papers, to advance AI use in kidney disease drug discovery and beyond If you'd like to stay tuned for the 2027 edition of the 9th CKD Summit, register your interest here... 🔗https://ter.li/yf88yw #CKDSummit #CKD3 #CKDresearch #CKDDrugDevelopment #NephrologyResearch #KidneyResearch #KidneyDrugDevelopment #ChronicKidneyDisease #CKDDrugDiscovery
Experience & Education
-
Multiomic Health
********** * ***** ********* *******
-
******** *******
******* *********** *******
-
****** ******* ********
*** ********* ********
-
************* ********* ** ********** * ***** ****** ** **********
** undefined undefined
-
-
********* ** ********* **
*** undefined
-
View Robert’s full experience
See their title, tenure and more.
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Publications
-
Biopharma R&D Partnerships: From David & Goliath to Networked R&D
Phizz Rx Publishing
See publicationDrawing upon the partnering experiences of more than forty different organizations, this book is about asymmetric David & Goliath R&D partnerships—collaborative arrangements between smaller bioscience firms or academic laboratories (David) with large multinational pharmaceutical corporations (Goliath) to discover, develop and commercialize innovative new drugs.
-
Creating a Culture of Productivity and Collaborative Innovation: Orion’s R&D Transformation
Research-Technology Management (RTM) Journal
Comprehensive case study of how Orion Pharma's R&D organization was transformed to implement a results-oriented "open R&D" model through proactive culture change.
Other authorsSee publication -
Transforming Biomedical R&D: Reflections on Two Decades of R&D Improvement Initiatives
Unleash Team Ltd - White Paper
See publicationOver the past two decades, biomedical companies have learnt painfully that industrialised management of R&D does not deliver. They are now putting the emphasis back on people, relying on human ingenuity and teamwork to innovate – by focusing their people and by adopting an open architecture.
View Robert’s full profile
-
See who you know in common
-
Get introduced
-
Contact Robert directly
Other similar profiles
-
Kate Moss (nee Watkins)
Kate Moss (nee Watkins)
Dynamic business consultant embedded within the Pharmaceutical & Lifesciences Industry. Futurist and connected thinker challenging the status quo and creating solutions with clients to enable accelerated delivery of diagnostics, drugs, devices and/or data.<br><br>My early years in Commercial strongly influenced how I subsequently approached Clinical Development. Designing programmes directly with patients and health care professionals, delivering clinical evidence as quickly as possible which was valued by decision makers and accelerated product accessibility. <br><br>As a Management Consultant this experience has been invaluable working with Pharmaceutical and other Lifescience organisations as they improve productivity and Quality in R&D, shift culture to embrace societal change or develop new skills & implement exciting technologies. I'm grateful for the trust my clients put in me and my team as we partner across the value chain to change the way they work. <br><br>At Baringa we are establishing a Pharmaceutical and Lifesciences practice focused on industry insights, delivering new ideas and implementing them with pragmatism. Our culture is unique with collaboration at it's core and a desire to always do the right thing for our clients and our team.
2K followersGreater Cambridge Area
Explore more posts
-
Jonathan Tobin
Brandon Capital • 10K followers
This is a thorough, timely and well-written report on UK university-investor links by Tony Hickson at Cancer Research Horizons; and thank you for specifically mentioning Brandon Capital in the context of the BioCatalyst collaboration we operate across >50 medical research institutes across Australasia. This model has given us unrivalled visibility and access to early-stage ideas, and created collaborations and transparency across the ecosystem. Three points jumped out at me in Tony's report: 1) UK universities produce large numbers (hundreds) of companies, but very few (5%) ever raise significant money (>£100m). Quality always trumps quantity in company creation. 2) Historically, a relative shortage of sector-specific and unconstrained (pre)seed-stage investors that can deploy meaningful amounts of cash (>£5m) very early - crucial for creating new companies that have "legs". 3) >70% of large and late-stage venture funding (>£100m) is coming from non-UK funds. There are pros and cons to this - it shows the UK sector is robust, resilient and globally attractive, but also that much of the economic benefit is ultimately exported, and UK funds are shouldering too much early risk (certainly in biotech where significant up-rounds are rare, therefore only investing early without the means to follow-on is not economically rewarded). https://lnkd.in/ei-KgbwP
84
2 Comments -
Pierre Socha
Amadeus Capital Partners • 25K followers
This is a profound step-change for #prostatecancer detection and management. The UK NHS is deploying Quibim QP-Prostate across key hospitals to make MRI the new standard for the early diagnosis of prostate cancer. Quibim is a global leader in virtual biopsies. Patients in the UK will soon have access to their MRI-based test that autonomously localizes tumors, stages them and more importantly flags high virulence cases. All of it in a non-invasive and painless way. No more unnecessary biopsies. More aggressive cancers will be detected earlier. More lives will be saved.
22
2 Comments -
Anna M. Detert
4K followers
I’m delighted to share Gloucester Ventures' latest thought leadership, Part II in the three-part series, “The Future of Precision Diagnostics". In Part I, we showed how AI/ ML has enabled innovations in detecting disease with greater sensitivity and specificity. In Part II, we predict how generative and agentic AI will unlock the next wave of precision diagnostics opportunities. We start with the diagnostics problem statement – five key challenges – such as limited data access and usability, proliferation of tests and less attractive revenue models. We then turn to the challenges into five ‘Must Have’s’ that AI can enable: - Ready to use, valued quality data via independent data exchanges - Regulation focused on quality of AI in clinical diagnostics - Harmonized precision diagnostics platforms vs. tests - Predictive Dx decisioning, powered by genAI, populated by agents - Evolved business models more akin to AI-native companies And finally we outline what this means for investors - with five potential bets in and around precision diagnostics. Many thanks to all of the superb contributors to this article: Tzvika Barkai, Reena Bhargava, MD, FACP Burns C. Blaxall, PhD, Ed Esplin, MD, PhD, FACMG, CGAF, FACP, Mark Hughes, Monica Isgut, PhD . Christopher Kan Dimitri Krylov, PhD, Jeffrey Edward Miller, Ph.D., Mika Newton, Dhruvajyoti Roy, Ph.D. ,Alexander Sicular, Karthik Suresh, and also to Robyn Baker for her excellent design work. The slides from the article are below; for the full article viewing, visit our website https://lnkd.in/eVBhEFEm media. Look forward to continuing the dialogue! #Gloucester Ventures #Precision Diagnostics #AI in diagnostics #AI in Healthcare
20
4 Comments -
Donal O'Shea
Deciphex • 5K followers
Delighted to announce that Deciphex has secured a further €15m in venture debt from Claret Capital Partners to accelerate our US expansion and UK growth. Pathology underpins 95% of clinical care pathways, yet healthcare systems globally are struggling with increasing case volumes, growing complexity, and declining pathologist capacity. Our Diagnexia platform helps NHS trusts and healthcare providers maintain diagnostic quality and reduce backlogs by providing on-demand access to subspecialty expertise, while Patholytix helps pharmaceutical companies accelerate drug development through optimized preclinical safety assessments. We're seeing tremendous demand across both markets. Venture debt gives us the capital efficiency to execute aggressively on our growth plans while building toward our next equity milestone - with a clear goal of becoming the leading histopathology reporting provider in the UK by 2027. Thanks to Joey Mason and the Claret team for their partnership since 2023 and their continued confidence in our execution. #DigitalPathology #AIinHealthcare #Medtech
176
12 Comments -
John E. Milad
ERS Genomics • 7K followers
I've launched a new Substack called Backed By Reality (https://lnkd.in/ejNZtkZs). This is my attempt, as a healthcare operator and investor, to separate signal from noise in the AI conversation. Here's why I'm writing about this now: We're witnessing the largest capital expenditure program in human history. Worldwide AI spending will hit $2.5 trillion this year — thirteen times the inflation-adjusted cost of the Apollo program. OpenAI just closed a $110 billion round. Amazon plans $200 billion on AI infrastructure alone. The ambitions match the capital. Anthropic's CEO describes the end state as "a country of geniuses in a data center" working on humanity's hardest problems. McKinsey estimates 57% of work hours could be automated. Goldman Sachs projects 300 million jobs displaced globally. But most people's experience with AI begins and ends with a chatbot. They have little sense of what these systems can already do or what's coming next. My perspective comes from over 25 years operating and investing in healthcare and the life sciences, and from immersing myself in the AI world over the past year. I've spoken with engineers, investors, and innovators on the frontlines, and I've been getting hands-on with AI tools and systems to develop my personal intuition for both the capabilities and limitations of this technology. Healthcare faces chronic labor shortages, mounting regulatory complexity, and unsustainable cost growth. AI could compress years of drug discovery into months, transform diagnostics, and help close workforce gaps. But it could also create new vulnerabilities we haven't anticipated. The signal matters because the stakes are civilizational. The noise obscures what's actually happening and who will benefit. My first piece sets the scene: what's happening and why I'm writing about it. Subsequent pieces will explore what it actually means for operators, investors, and anyone trying to build in this space. #AI #Healthcare #Venture #Substack #Innovation
16
2 Comments -
Maina Bhaman
2K followers
Britain has world-class science. What it needs now is world-class ambition to match it. I was delighted to share my perspective with In Vivo on the state of UK biotech, and what it will take to build a truly competitive ecosystem. → Funding is necessary, but not sufficient. Growth policy is the real differentiator. → We can't outspend China. But agility, NHS data, AI, and talent can be our edge. → The private sector needs to think bigger. Global intent from day one, not as an afterthought. The ingredients are there. Scientific excellence must be matched with operational ambition. By 2030, the UK should be the most founder-friendly biotech market in Europe. But only if we build that way, deliberately and urgently. Full article in the comments 👇
208
7 Comments -
Nisa Leung
Aulis Capital • 15K followers
Merck has entered a strategic collaboration with U.K.-based medtech firm Calla Lily Clinical Care to advance its innovative Callavid device. This next-gen intravaginal drug delivery system, designed like a tampon with an integrated absorbent liner, promises to transform how vaginal therapeutics are administered, addressing key limitations of current methods. Callavid aims to provide a leak-resistant, highly accurate alternative to traditional vaginal pessaries, eliminating the need for patients to remain in a fixed position post-dose. The device is currently being tested in clinical trials for applications like preventing miscarriage and supporting fertility treatments. With Merck's financial and strategic backing, this collaboration could pave the way for more convenient, efficient, and user-friendly therapeutic solutions, especially in women's health. #MedTech #DrugDelivery #WomensHealth #InnovationInHealthcare #Therapeutics https://lnkd.in/gzqWZ7RF
35
-
Alan Murray
Conceivable Life Sciences • 7K followers
"We achieved what Nobel Laureate Robert Edwards set out: accessibility." That's our Chief Medical Advisor and Edwards protege Charles Kingsland describing how he built the UK's pioneering NHS IVF facility in Liverpool—where patients could walk off the street and receive 2-3 cycles of treatment, no matter their finances. But what strikes me most isn't just what Kingsland accomplished. It's how he accomplished it. His solution to scaling access? Education and upskilling. "As a professor, I didn't want to be the most expensive ultrasonographer on the unit," Kingsland explains. So he trained nurses to perform oocyte retrievals and embryo transfers. He created MSc courses, PhD programs, and continuous learning pathways. He built a self-contained training ecosystem that attracted research fellows from around the world—including, as he notes my co-founder, "a young gynecologist called Alejandro." We're facing a critical embryologist shortage. And the average REI would need to oversee thousands of cycles annually to meet demand. Kingsland's approach offers a blueprint: strategic upskilling that expands the workforce while maintaining quality. Train nurses and physician assistants for specific procedures. Create structured pathways from general lab work into specialized fertility roles. Build educational programs that turn interested professionals into skilled practitioners. And yes—combine it with automation that amplifies what skilled professionals can accomplish. Kingsland maintained efficiency by ensuring the most expensive expertise focused on tasks that truly required it. Automation does the same thing: it handles repetitive, labor-intensive steps so embryologists can oversee multiple systems, manage complex cases, and mentor the next generation. Accessibility through education. Accessibility through smart workforce development. Accessibility through technology that extends expertise rather than replacing it. Kingsland proved it works in Liverpool. We need the same commitment to training, the same willingness to rethink traditional roles, and the same focus on building sustainable systems that serve everyone—not just those who can afford what has become expensive concierge medicine. Thank you, Charles, for showing what's possible when you prioritize accessibility from the start. And congratulations on training Alejandro Chavez-Badiola, MD, PhD, my co-founder who's now helping us to scale that vision globally.
41
4 Comments -
Katie Lockwood
Twin Path Ventures • 5K followers
Delighted to see that HotHouse Therapeutics, a spin out from the world-leading plant biosynthetic lab of Professor Anne Osbourn at the John Innes Centre has emerged from stealth mode with ~£3m in seed funding. There is a quite a story behind this one. In the vaccine industry there is global dependence on a critical adjuvant, QS-21. Today, this comes from the bark of a slow-growing Chilean tree, Quillaja saponaria. Purifying QS-21 destroys the tree, creating issues of sustainability as well as supply chain confidence. Supply chain is also threatened by the rise of wild fires in places where the tree grows. QS21 cannot, however, be easily made in the lab. It has been considered one of the hardest challenges in synthetic chemistry (complex assembly sequence, multiple chiral cores, bonds that will spontaneously break if exposed to the wrong pH during synthesis). In fact it takes 76 steps in the lab. Plants are quite good at reaching interesting chemical spaces and Hothouse was built around the question: what if you could use all of the tools of a plant (reservoir of enzymes, cellular architecture, etc) to turn it into a living laboratory? HotHouse team has spent years mastering this particular biochemical space building up a locker of proprietary plant genetic and omics data in it. Through the use of advanced bioinformatics (genome mining, pathway discovery), protein based LLMs and adaptive knowledge graphs, they have built a platform to design biosynthetic pathways, solve this bottleneck and productise complex plant chemistry. In 2024, they managed to identify a 20-step biosynthetic pathway of QS-21 and cloned it into tobacco plant. The goal here is to reprogram plants to sustainability produce novel adjuvants. These are plants that can be grown more easily (and here in the UK), faster and where extraction can come from the leaves rather than the bark. We are really excited about the broader potential of this approach especially in light of recent breakthroughs in synthetic biology (with the Evo-1 and Evo-2 models). Twin Path Ventures is delighted to form a syndicate of stellar investors (Hassan Mahmudul SynBioVen Wren Capital LLP UK Innovation & Science Seed Fund [UKI2S] Antoine Pechin) Congratulations to David Sheppard Phil Spence Ivan Griffin and the rest of the team. https://lnkd.in/egzWAP3H
32
1 Comment -
Simon Goldman
AlbionVC • 3K followers
Couldn’t agree more with Anne Lane from UCL Business Ltd here. The UK is uniquely positioned in the life sciences and a few policy tweaks - including beefing up a number of existing support channels within universities and across industry - could help to significantly propel globally impactful innovation.
12
-
Liam Taylor
Concinnity Genetics • 15K followers
Pain and Cosmetics discovery and efficacy Scientists/Researchers SENSORY NEURON New eBook! In this free eBook, you’ll learn about: • The limitations of legacy models in pain and neurotoxicity research • How iPSC-derived sensory neurons are bridging the bench-to-bedside gap • The unique capabilities of Axol’s axoCells, optimized for both multi-well plates and microfluidic platforms • Real-world applications in pain modeling, skin biology, anti-aging research, cosmetic safety, and more • The benefits of our newly reformulated Sensory Neuron 2.0 kit Download your free copy today and redefine your research potential: https://hubs.la/Q03t7nd70 Enjoy Liam #PNS #cosmetics #skin #research #pain #drugdiscovery #neurons #cellculture #lifescience #biotech #neurotoxicity #invitro #MPS2025
11
-
Jørgen Søberg Petersen
Novo Holdings • 4K followers
I am delighted to share the Novo Holdings Seed Investments Review for 2025. This review highlights a series of financing rounds exceeding $750 million for our existing portfolio companies. Moreover, it showcases four new stealth-stage biotech companies and new investments made by our Quantum team. Hopefully, you will find the insights and developments outlined in the review to be both informative and inspiring.
83
1 Comment -
Laurent Audoly
PriveBio • 12K followers
Reposting this thoughtful analysis from Oppenheimer & Co. Inc. The report underscores a shift many of us in the field have been observing: longevity is increasingly defined not by lifespan extension alone, but by the biological processes that determine healthspan — metabolic integrity, organ resilience, and the burden of chronic fibro-inflammatory disease. What resonates most is the recognition that cardiometabolic dysfunction sits at the core of these interconnected pathways. The fibro-inflammatory remodeling that accumulates across organs is not a downstream consequence — it’s a central driver of decline. At PriveBio , our focus is to quantify these mechanisms with precision and develop targeted biologics that intervene upstream, where fibrosis, inflammation, and metabolic stress converge. The inclusion of PRV-101 in this report reflects the growing importance of precision frameworks and biomarker-enabled development in this next phase of therapeutics. A timely piece of analysis capturing where the field is heading — from treating disease to preserving long-term physiological function. #ObesityTherapeutics #CardiometabolicDisease #CardiorenalDisease # CKM #PrecisionMedicine #Fibroinflammation #Biotech #ObesityInnovation #PriveBio #Longevity #Healthspan #Lifespan #Longevity #BiotechInnovation #PriveBio
15
1 Comment -
Hakim Yadi Ph.D. OBE
Baringa • 9K followers
A pleasure to support Global Counsel round table on behalf of Baringa on the subject of 'The role of private investment in the UK healthcare system'. Thank you to Charlie Norell, Daniel Mahony and Dr Harpreet Sood for the invitation to contribute to such a timely discussion. The discussion brought together investors, founders, and officials from across life sciences, medtech and digital health. Participants explored how private capital could complement NHS reform and how the health system might engage more confidently with commercial partners to accelerate innovation and productivity. While the UK continues to attract substantial venture and private-equity flows into biopharma and health-tech companies, those investments seldom translate into scaled NHS deployment or measurable patient benefit. The conversation focused on what cultural, structural and procedural changes could close this gap and create a more predictable environment for partnership. 🔗 to the paper here: https://lnkd.in/edfSaXnu
16
-
Adrian Field
Embankment Equity • 3K followers
Oxford BioTherapeutics has announced an exciting partnership with GSK focused on antibody-drug conjugates (ADCs) and other antibody therapies for cancer. This collaboration serves as another validation of the technology and capabilities of OBT, especially following their earlier deal with Roche this year. For more details, you can read the full announcement here: https://lnkd.in/eQ-fe37s
42
2 Comments -
Joe Healey
NanoSyrinx • 4K followers
NanoSyrinx was recently featured in Nature Portfolio 's Biopharma Dealmakers explaining how our Nanosyringe technology could revolutionise everything from #drugdiscovery, all the way through to therapeutic development. Read the article here: https://lnkd.in/ey9hEbRE We're super excited about what this can mean for solving #pharma and #biotech #drugdelivery challenges, and are keen to speak to partners who are trying to tap into "undruggable" biology. Many thanks to the BPDM team for helping pull this all together Raveena B. Mark Zipkin Carmen D'Cruz #engineeringbiology
132
4 Comments -
Alexis Frentz
Elaia • 9K followers
🚀 Big news from our portfolio: SeqOne has acquired Congenica, the UK leader in clinical genomics. This comes just months after SeqOne’s acquisition of Life & Soft, cementing its position as the largest global software pure player in genomic medicine. The combined group now supports 160+ labs across 30+ countries, powering over 200,000 patient analyses in 2025. Why it matters: sequencing a genome has become cheap and fast—the real challenge is interpreting data at scale. By combining SeqOne’s AI-driven NGS analysis with Congenica’s clinical decision-support platform, the company is breaking through this bottleneck, delivering actionable insights for faster rare disease diagnoses and more precise oncology care. 👏 Congrats to Martin Dubuc and the SeqOne team for driving this major step forward in genomic medicine. 🔗 Read more in Tech.eu: https://lnkd.in/eyeEWvWE
47
1 Comment
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Robert Thong
-
Robert Vu
Vietnam -
Robert Thong
Monterey Park, CA -
Robert Thong
Greater Melbourne Area -
Robert Thong
Kuala Lumpur
6 others named Robert Thong are on LinkedIn
See others named Robert Thong